{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:30:35Z","timestamp":1770903035734,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1038\/gt.2015.105","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T16:02:32Z","timestamp":1447948952000},"page":"135-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility"],"prefix":"10.1038","volume":"23","author":[{"given":"P-Y","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Swain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A L","family":"Kunkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C-Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B J","family":"Hutzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K A","family":"Streby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M H","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Dipasquale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R","family":"Stanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Conner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T H","family":"van Kuppevelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J C","family":"Glorioso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T P","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"key":"BFgt2015105_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.pcl.2007.10.014","volume":"55","author":"JR Park","year":"2008","unstructured":"Park JR, Eggert A, Caron H . Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am 2008; 55: 97\u2013120; x.","journal-title":"Pediatr Clin North Am"},{"key":"BFgt2015105_CR2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.trsl.2012.12.010","volume":"161","author":"MR Patel","year":"2013","unstructured":"Patel MR, Kratzke RA . Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res 2013; 161: 355\u2013364.","journal-title":"Transl Res"},{"key":"BFgt2015105_CR3","doi-asserted-by":"publisher","first-page":"e28694","DOI":"10.4161\/onci.28694","volume":"3","author":"J Pol","year":"2014","unstructured":"Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I et al. Trial watch: oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3: e28694.","journal-title":"Oncoimmunology"},{"key":"BFgt2015105_CR4","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 2015; 33: 2780\u20132788.","journal-title":"J Clin Oncol"},{"key":"BFgt2015105_CR5","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1056\/NEJM199904223401608","volume":"340","author":"HH Balfour Jr","year":"1999","unstructured":"Balfour HH Jr . Antiviral drugs. N Engl J Med 1999; 340: 1255\u20131268.","journal-title":"N Engl J Med"},{"key":"BFgt2015105_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1462-5822.2004.00389.x","volume":"6","author":"PG Spear","year":"2004","unstructured":"Spear PG . Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 2004; 6: 401\u2013410.","journal-title":"Cell Microbiol"},{"key":"BFgt2015105_CR7","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1210\/jc.2007-0040","volume":"92","author":"YY Huang","year":"2007","unstructured":"Huang YY, Yu Z, Lin SF, Li S, Fong Y, Wong RJ . Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 2007; 92: 1965\u20131970.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFgt2015105_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/sj.mt.6300009","volume":"15","author":"Z Yu","year":"2007","unstructured":"Yu Z, Adusumilli PS, Eisenberg DP, Darr E, Ghossein RA, Li S et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther 2007; 15: 103\u2013113.","journal-title":"Mol Ther"},{"key":"BFgt2015105_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-009-9926-0","volume":"95","author":"GK Friedman","year":"2009","unstructured":"Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM et al. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. Journal of Neuro-Oncology 2009; 95: 199\u2013209.","journal-title":"Journal of Neuro-Oncology"},{"key":"BFgt2015105_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/gt.2012.93","volume":"20","author":"PY Wang","year":"2013","unstructured":"Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H et al. Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther 2013; 20: 761\u2013769.","journal-title":"Gene Ther"},{"key":"BFgt2015105_CR11","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/gt.2014.72","volume":"21","author":"JD Jackson","year":"2014","unstructured":"Jackson JD, McMorris AM, Roth JC, Coleman JM, Whitley RJ, Gillespie GY et al. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther 2014; 21: 984\u2013990.","journal-title":"Gene Ther"},{"key":"BFgt2015105_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/pbc.20268","volume":"44","author":"N Parikh","year":"2005","unstructured":"Parikh N, Currier MA, Adams LC, Mahller YY, DiPasquale B, Collins MH et al. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 2005; 44: 469\u2013478.","journal-title":"Pediatr Blood Cancer"},{"key":"BFgt2015105_CR13","doi-asserted-by":"publisher","first-page":"e4235","DOI":"10.1371\/journal.pone.0004235","volume":"4","author":"YY Mahller","year":"2009","unstructured":"Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009; 4: e4235.","journal-title":"PLoS One"},{"key":"BFgt2015105_CR14","doi-asserted-by":"publisher","first-page":"e77753","DOI":"10.1371\/journal.pone.0077753","volume":"8","author":"LA Gillory","year":"2013","unstructured":"Gillory LA, Megison ML, Stewart JE, Mroczek-Musulman E, Nabers HC, Waters AM et al. Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma. PLoS One 2013; 8: e77753.","journal-title":"PLoS One"},{"key":"BFgt2015105_CR15","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1128\/JVI.72.9.7563-7568.1998","volume":"72","author":"P Desai","year":"1998","unstructured":"Desai P, Person S . Incorporation of the green fluorescent protein into the herpes simplex virus type 1 capsid. J Virol 1998; 72: 7563\u20137568.","journal-title":"J Virol"},{"key":"BFgt2015105_CR16","doi-asserted-by":"publisher","first-page":"8970","DOI":"10.1128\/JVI.00296-06","volume":"80","author":"V Tiwari","year":"2006","unstructured":"Tiwari V, Clement C, Xu D, Valyi-Nagy T, Yue BY, Liu J et al. Role for 3-O-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts. J Virol 2006; 80: 8970\u20138980.","journal-title":"J Virol"},{"key":"BFgt2015105_CR17","doi-asserted-by":"publisher","first-page":"264350","DOI":"10.1155\/2011\/264350","volume":"2011","author":"S Choudhary","year":"2011","unstructured":"Choudhary S, Marquez M, Alencastro F, Spors F, Zhao Y, Tiwari V . Herpes simplex virus type-1 (HSV-1) entry into human mesenchymal stem cells is heavily dependent on heparan sulfate. J Biomed Biotechnol 2011; 2011: 264350.","journal-title":"J Biomed Biotechnol"},{"key":"BFgt2015105_CR18","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.3390\/molecules20022707","volume":"20","author":"V Tiwari","year":"2015","unstructured":"Tiwari V, Tarbutton MS, Shukla D . Diversity of heparan sulfate and HSV entry: basic understanding and treatment strategies. Molecules 2015; 20: 2707\u20132727.","journal-title":"Molecules"},{"key":"BFgt2015105_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1006\/viro.1998.9218","volume":"246","author":"MS Warner","year":"1998","unstructured":"Warner MS, Geraghty RJ, Martinez WM, Montgomery RI, Whitbeck JC, Xu R et al. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 1998; 246: 179\u2013189.","journal-title":"Virology"},{"key":"BFgt2015105_CR20","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/JVI.74.3.1267-1274.2000","volume":"74","author":"M Lopez","year":"2000","unstructured":"Lopez M, Cocchi F, Menotti L, Avitabile E, Dubreuil P, Campadelli-Fiume G . Nectin2alpha (PRR2alpha or HveB) and nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the Leu25Pro substitution in glycoprotein D. J Virol 2000; 74: 1267\u20131274.","journal-title":"J Virol"},{"key":"BFgt2015105_CR21","doi-asserted-by":"publisher","first-page":"14010","DOI":"10.1038\/mto.2014.10","volume":"1","author":"JL Leddon","year":"2015","unstructured":"Leddon JL, Chen C-Y, Currier MA, Wang P-Y, Jung FA, Denton NL, Cripe KM et al. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol Ther Oncolytics 2015; 1: 14010.","journal-title":"Mol Ther Oncolytics"},{"key":"BFgt2015105_CR22","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1128\/JVI.01449-08","volume":"83","author":"H Uchida","year":"2009","unstructured":"Uchida H, Shah WA, Ozuer A, Frampton AR Jr, Goins WF, Grandi P et al. Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. J Virol 2009; 83: 2951\u20132961.","journal-title":"J Virol"},{"key":"BFgt2015105_CR23","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3390\/v1030979","volume":"1","author":"T Chew","year":"2009","unstructured":"Chew T, Taylor KE, Mossman KL . Innate and adaptive immune responses to herpes simplex virus. Viruses 2009; 1: 979\u20131002.","journal-title":"Viruses"},{"key":"BFgt2015105_CR24","first-page":"5714","volume":"60","author":"CG Miller","year":"2000","unstructured":"Miller CG, Fraser NW . Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res 2000; 60: 5714\u20135722.","journal-title":"Cancer Res"},{"key":"BFgt2015105_CR25","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/nm.3013","volume":"18","author":"CA Alvarez-Breckenridge","year":"2012","unstructured":"Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 2012; 18: 1827\u20131834.","journal-title":"Nat Med"},{"key":"BFgt2015105_CR26","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/mt.2013.39","volume":"21","author":"MA Currier","year":"2013","unstructured":"Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S et al. VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther 2013; 21: 1014\u20131023.","journal-title":"Mol Ther"},{"key":"BFgt2015105_CR27","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/mt.2014.101","volume":"22","author":"AH Thorne","year":"2014","unstructured":"Thorne AH, Meisen WH, Russell L, Yoo JY, Bolyard CM, Lathia JD et al. Role of cysteine-rich 61 protein (CCN1) in macrophage-mediated oncolytic herpes simplex virus clearance. Mol Ther 2014; 22: 1678\u20131687.","journal-title":"Mol Ther"},{"key":"BFgt2015105_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/mt.2013.238","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Simmons G, Pol JG, Lichty BD, Halford WP, Mossman KL . Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy. Mol Ther 2014; 22: 123\u2013131.","journal-title":"Mol Ther"},{"key":"BFgt2015105_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1099\/0022-1317-72-3-631","volume":"72","author":"AR MacLean","year":"1991","unstructured":"MacLean AR, ul-Fareed M, Robertson L, Harland J, Brown SM . Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72: 631\u2013639.","journal-title":"J Gen Virol"},{"key":"BFgt2015105_CR30","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1074\/jbc.M506357200","volume":"281","author":"GB Ten Dam","year":"2006","unstructured":"Ten Dam GB, Kurup S, van de Westerlo EM, Versteeg EM, Lindahl U, Spillmann D et al. 3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3. J Biol Chem. 2006; 281: 4654\u20134662.","journal-title":"J Biol Chem."}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt2015105","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt2015105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T12:08:52Z","timestamp":1648555732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt2015105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["BFgt2015105"],"URL":"https:\/\/doi.org\/10.1038\/gt.2015.105","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]},"assertion":[{"value":"1 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JC is an employee of Virttu Biologics Ltd. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}